Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Anticancer effects of an XPO1 inhibitor (selinexor) with sotorasib following omeprazole preconditioning in KRAS G12C-mutant non-small cell lung cancer cells in vitro and in a mouse tumor xenograft. Local targets link to admitted publications; unresolved targets remain external evidence.
Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive State
10.1158/2159-8290.cd-15-1105 · 2016 · External reference
Discovery of Fulzerasib (GFH925) for the treatment of KRAS G12C-mutated solid tumors
10.1021/acs.jmedchem.4c03183 · 2025 · External reference
Fulzerasib plus cetuximab in first-line KRASG12C-mutated non-small-cell lung cancer (KROCUS): a single-arm, multicentre, phase 1b/2 trial
10.1016/s1470-2045(25)00764-8 · 2026 · External reference
Cetuximab co-treatment with KRAS G12C inhibitors fulzerasib and sotorasib in human KRAS G12C non-small cell lung cancer cells
10.1038/s41420-026-02998-z · 2026 · External reference
Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition
10.1038/s41586-019-1884-x · 2020 · External reference
Scribble mis-localization induces adaptive resistance to KRAS G12C inhibitors through feedback activation of MAPK signaling mediated by YAP-induced MRAS
10.1038/s43018-023-00575-2 · 2023 · External reference
Mechanisms of resistance to KRAS inhibitors: cancer cells' Strategic use of normal cellular Mechanisms to adapt
10.1111/cas.16441 · 2025 · External reference
RAS proteins and their regulators in Human disease
10.1016/j.cell.2017.06.009 · 2017 · External reference
Sotorasib for lung cancers with KRAS p.G12C mutation
10.1056/nejmoa2103695 · 2021 · External reference
Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS(G12C) mutation: a randomised, open-label, phase 3 trial
10.1016/s0140-6736(23)00221-0 · 2023 · External reference
Molecular determinants of sotorasib clinical efficacy in KRAS(G12C)-mutated non-small-cell lung cancer
10.1038/s41591-025-03732-5 · 2025 · External reference
Spatial and temporal coordination of mitosis by Ran GTPase
10.1038/nrm2410 · 2008 · External reference
The pro-oncogenic noncanonical activity of a RAS•GTP:ranGAP1 complex facilitates nuclear protein export
10.1038/s43018-024-00847-5 · 2024 · External reference
AURKA/PHB2 signaling drives acquired resistance to KRAS G12C inhibitors in KRAS G12C-mutant NSCLC
10.1038/s41420-026-03080-4 · 2026 · External reference
Antitumor effects of a novel chromosome region maintenance 1 (CRM1) inhibitor on non-small cell lung cancer cells in vitro and in mouse tumor xenografts
2014 · External reference
XPO1 (CRM1) inhibition represses STAT3 activation to drive a survivin-dependent oncogenic switch in triple-negative breast cancer
10.1158/1535-7163.mct-13-0416 · 2014 · External reference
KPT-330 has antitumour activity against non-small cell lung cancer
10.1038/bjc.2014.260 · 2014 · External reference
XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer
10.1038/nature19771 · 2016 · External reference
Inhibitor of the nuclear transport protein XPO1 enhances the anticancer efficacy of KRAS G12C inhibitors in preclinical models of KRAS G12C-mutant cancers
10.1158/2767-9764.crc-21-0176 · 2022 · External reference
KRAS-mutant non-small cell lung cancer (NSCLC) therapy based on tepotinib and omeprazole combination
10.1186/s12964-024-01667-x · 2024 · External reference
AURKA/PHB2 signaling drives acquired resistance to KRAS G12C inhibitors in KRAS G12C-mutant NSCLC
2026 · External reference
AURKA suppresses NCOA4-mediated ferritinophagy to enhance sorafenib resistance in hepatocellular carcinoma
2026 · External reference
Modulation of the proteostasis network promotes tumor resistance to oncogenic KRAS inhibitors
10.1126/science.abn4180 · 2023 · External reference
HMGB1 Expression levels correlate with response to immunotherapy in non-small cell lung cancer
2024 · External reference
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
10.1038/nature08460 · 2009 · External reference
Therapeutic targeting of nuclear export inhibition in lung cancer
10.1016/j.jtho.2017.06.013 · 2017 · External reference
Oral selinexor-dexamethasone for triple-class refractory multiple myeloma
10.1056/nejmoa1903455 · 2019 · External reference
XPO1 Inhibitor selinexor overcomes intrinsic ibrutinib resistance in mantle cell lymphoma via nuclear retention of IκB
10.1158/1535-7163.mct-17-0789-atr · 2018 · External reference
Oral eltanexor treatment of patients with higher-risk myelodysplastic syndrome refractory to hypomethylating agents
10.1186/s13045-022-01319-y · 2022 · External reference
Verdinexor, a selective inhibitor of nuclear exportin 1, inhibits the proliferation and migration of esophageal cancer via XPO1/c-Myc/FOSL1 axis
10.7150/ijbs.66612 · 2022 · External reference
Phase I/II trial of Exportin 1 inhibitor Selinexor plus Docetaxel in previously treated, advanced KRAS-mutant non-small cell lung cancer
10.1158/1078-0432.ccr-24-1722 · 2025 · External reference
Parallel phase II clinical trials of Selinexor in patients with advanced thymoma and thymic carcinoma
2025 · External reference
Abrogation of oncogenic RAS signaling by a RAS(ON) inhibitor doublet primes immune-refractory KRASG12C-mutant NSCLC for Immune checkpoint blockade
10.1158/2159-8290.cd-25-1616 · 2026 · External reference
SREBP-1 increases glucose uptake to promote tumor resistance to lysosome inhibition
10.1126/scitranslmed.adx6873 · 2026 · External reference
Emerging landscape of KRAS inhibitors in cancer treatment
10.1016/j.ccell.2026.01.001 · 2026 · External reference
Daraxonrasib or chemotherapy in previously treated metastatic pancreatic cancer
10.1056/nejmoa2605555 · 2026 · External reference
KRAS G12C inhibitor combination therapies: current evidence and challenge
10.3389/fonc.2024.1380584 · 2024 · External reference
Response and resistance to RAS inhibition in cancer
10.1158/2159-8290.cd-25-0349 · 2025 · External reference
Expression of LIFR in tumor and SHOC2, YAP1 in plasma mRNA as potential biomarkers in KRAS (G12C) NSCLC
10.1038/s41598-026-48898-1 · 2026 · External reference
Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer
10.1038/s41586-024-07379-z · 2024 · External reference
Exportin 1 inhibition prevents neuroendocrine transformation through SOX2 down-regulation in lung and prostate cancers
10.1126/scitranslmed.adf7006 · 2023 · External reference
P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia
10.1038/s43018-022-00394-x · 2022 · External reference
Targeting purinergic receptor P2Y2 prevents the growth of pancreatic ductal adenocarcinoma by inhibiting cancer cell glycolysis
10.1158/1078-0432.ccr-18-2297 · 2019 · External reference
Targeting XPO1 for fighting relapsed/refractory diseases: the research progress of XPO1 inhibitors
10.1016/j.bioorg.2024.108073 · 2025 · External reference
